aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Totus Medicines, founded with the mission to revolutionize chemical biology, focuses on creating life-changing treatments for previously untreatable diseases. Leveraging covalent molecules, Totus aims to unlock undruggable targets for both non-covalent and covalent drug development. Their innovative platform enables the discovery of drugs with unprecedented volume, speed, and efficiency, aiming to develop a comprehensive catalog of therapeutics across the entire human genome.
Notable figures associated with Totus Medicines include leading scientists and industry experts in chemical biology and drug development. The company has garnered significant attention from investors due to its groundbreaking approach and potential to address unmet medical needs. Key achievements include the rapid identification of promising drug candidates and advancements in targeting previously undruggable proteins. Totus Medicines is poised to make a substantial impact on the pharmaceutical industry by providing new hope for patients with untreatable conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Drug Development
Technology
Biotech
Tags
Therapeutics
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
Global
When was Totus Medicines founded?
Totus Medicines was founded in 2020.
Where is Totus Medicines’s headquarters located?
Totus Medicines’s headquarters is located in Emeryville, CA, US.
When was Totus Medicines’s last funding round?
Totus Medicines’s most recent funding round was for $66M (USD) in December 2023.
How many employees does Totus Medicines have?
Totus Medicines has 40 employees as of Feb 4, 2024.
How much has Totus Medicines raised to-date?
As of July 05, 2023, Totus Medicines has raised a total of $106M (USD) since Dec 15, 2023.
Add Comparison
Total Raised to Date
$106M
USD
Last Update Dec 15, 2023
Last Deal Details
$66M
USD
Dec 15, 2023
Series B
Total Employees Over Time
40
As of Feb 2024
Totus Medicines Address
1480 64th St
Emeryville,
California
94608
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts